Moving On from AAV with Poseida Therapeutics' CEO, Mark Gergen
Jun 23, 2022•28 min•Season 1Ep. 26
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
We love to hear from our listeners. Send us a message.
Poseida Therapeutics is a broad platform technology company led by CEO, Mark Gergen. During this episode, Gergen explains how and why the company is moving away from AAV delivery in favor of nanoparticle delivery. He shares some of the biggest hurdles the CGT sector faces when it comes to the development of off-the-shelf therapies as well as the manufacturing challenges Poseida has had to overcome and how they did it.
For the best experience, listen in Metacast app for iOS or Android